ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QTTB vs LYEL // FORWARD P/E MULTIPLE

Q32 Bio Inc. (NASDAQ) VS. Lyell Immunopharma Inc. (NASDAQ) • 15-METRIC TALLY: QTTB 4 — LYEL 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QTTB VS. LYEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QTTB LYEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 QTTB /roic <GO>
EV/EBITDA & P/E Valuation 12.8x — — TIE /valuation <GO>
Free Cash Flow Yield -12.70% — — TIE /fcf-yield <GO>
Operating Margin 31.50% -60.00% +91.50 QTTB /operating-margins <GO>
Net Profit Margin 55.50% -60.00% +115.50 QTTB /net-margins <GO>
Revenue Growth (YoY) — -41.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.99 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 QTTB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.2 60.0 -11.80 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE 8.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $265.2M $270.5M -$5.3M LYEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QTTB REV LYEL REV QTTB GROSS % LYEL GROSS % QTTB FCF LYEL FCF
FY 2025 $53.7M $36.0K — — -$33.5M -$150.8M
FY 2024 $185.1M $61.0K — — -$67.8M -$162.9M
FY 2023 $1.2M $130.0K — — -$18.7M -$163.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QTTB // BETA —
LYEL // BETA —